Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon, D J; Neven, P; Chia, Set al.
2021 • In Annals of Oncology, 32 (8), p. 1015-1024
[en] BACKGROUND: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Here we present a new landmark in survival follow-up for a phase III cyclin-dependent kinases 4 and 6 inhibitor clinical trial in patients with ABC (median, 56.3 months).
PATIENTS AND METHODS: This phase III, randomized, double-blind, placebo-controlled trial was conducted at 174 sites (30 countries). Patients were men and postmenopausal women (age ≥18 years) with histologically/cytologically confirmed HR+/HER2- ABC. Patients could have received ≤1 line of endocrine therapy (ET) but no chemotherapy for ABC. Patients, assigned 2:1, were stratified by the presence/absence of liver/lung metastases and previous ET. Patients received intramuscular fulvestrant (500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1) with oral ribociclib (600 mg/day, 3 weeks on, 1 week off) or placebo. Efficacy analyses were by intention to treat. Safety was assessed in patients receiving ≥1 dose study treatment. OS was a secondary endpoint. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615; no longer enrolling).
RESULTS: Between 18 June 2015 and 10 June 2016, 726 patients were randomly assigned (484, ribociclib; 242, placebo). At data cut-off (30 October 2020), median OS (mOS) was 53.7 months (ribociclib) versus 41.5 months (placebo) [hazard ratio (HR), 0.73; 95% confidence interval (CI) 0.59-0.90]. Subgroup analyses were consistent with overall population. In the first-line setting, most patients in the ribociclib arm (∼60%) lived longer than median follow-up; mOS was 51.8 months in the placebo arm (HR, 0.64; 95% CI 0.46-0.88). In the second-line setting, mOS was 39.7 months (ribociclib) versus 33.7 months (placebo) (HR, 0.78; 95% CI 0.59-1.04). No apparent drug-drug interaction between ribociclib and fulvestrant or new safety signals were observed.
CONCLUSIONS: This analysis reported extended OS follow-up in MONALEESA-3. mOS was ∼12 months longer in patients with HR+/HER2- ABC treated with ribociclib plus fulvestrant compared with fulvestrant monotherapy.
Disciplines :
Oncology
Author, co-author :
Slamon, D J; David Geffen School of Medicine at UCLA, Los Angeles, USA. Electronic address: dslamon@mednet.ucla.edu
Neven, P; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium
Chia, S; British Columbia Cancer Agency, Vancouver, Canada
JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
De Laurentiis, M; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy
Im, S; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Petrakova, K; Masaryk Memorial Cancer Institute, Brno, Czech Republic
Valeria Bianchi, G; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
Martín, M; Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain
Nusch, A; Practice for Hematology and Internal Oncology, Velbert, Germany
Sonke, G S; Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands
De la Cruz-Merino, L; Hospital Universitario Virgen Macarena, Seville, Spain
Beck, J T; Highlands Oncology Group, Fayetteville, USA
Ji, Y; Novartis Pharmaceuticals Corporation, East Hanover, USA
Wang, C; Novartis Pharma AG, Basel, Switzerland
Deore, U; Novartis Pharmaceuticals Corporation, East Hanover, USA
Chakravartty, A; Novartis Pharmaceuticals Corporation, East Hanover, USA
Zarate, J P; Novartis Pharmaceuticals Corporation, East Hanover, USA
Taran, T; Novartis Pharma AG, Basel, Switzerland
Fasching, P A; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
This study was sponsored by Novartis. We thank the patients who participated in this trial, their families, and their caregivers; members of the data monitoring committee; members of the study steering committee; staff members who helped with the trial at each site; and Daniele Cary, PhD, of MediTech Media for medical editorial assistance with this manuscript. Ribociclib was discovered by Novartis Institutes for BioMedical Research in collaboration with Astex Pharmaceuticals. The study was funded by Novartis Pharmaceuticals Corporation. DJS reports board of directors (stock) and travel expenses from BioMarin; stock ownership, research funding, and travel expenses from Pfizer; advisory board, consulting, research funding, and travel expenses from Novartis; consulting from Eli Lilly; and stock ownership from Amgen and Seattle Genetics. SC reports that his institution received grants and personal fees for advisory boards from Novartis, Pfizer, Hoffmann-La Roche, and Eli Lilly, outside the submitted work. GJ reports personal fees from Novartis, during the conduct of the study; grants, personal fees, and non-financial support from Novartis, Roche, and Pfizer; personal fees and non-financial support from Lilly, Amgen, BMS, and AstraZeneca; personal fees from AbbVie and Daiichi-Sankyo; and non-financial support from Med-immune and Merck KGaA, outside the submitted work. MDL reports personal fees for speaker honoraria and advisory board honoraria from Novartis, AstraZeneca, Eli Lilly, and Pierre Fabre, outside the submitted work. SI reports grants from AstraZeneca, Pfizer, Eisai, and Daewoong; advisory and personal fees from AstraZeneca, Novartis, Hanmi, Pfizer, Eisai, Amgen, MediPacto, Roche, Eli Lilly, MSD, and GlaxoSmithKline; and non-financial support from Novartis. KP reports personal fees for advisory board from Novartis, AstraZeneca, Roche, Pfizer, and BMS, outside the submitted work. GVB reports personal fees for advisory board from Novartis and Eli Lilly, outside the submitted work. MM reports personal fees for speaker honoraria and honoraria for participation in advisory boards from Lilly and Pfizer; honoraria for participation in advisory boards from AstraZeneca, GlaxoSmithKline, Pharmamar, and Taiho Oncology; and research grants and honoraria for participation in advisory boards from Novartis and Roche-Genentech, outside the submitted work. AN reports consulting/advisory role, travel/accommodation/expenses, and research funding from Novartis and consulting/advisory role from Amgen during the conduct of the study. GSS reports institutional reimbursement for patient accrual and education and steering committee activities from Novartis and institutional research support from Merck, AstraZeneca, and Roche, outside the submitted work. LDLC-M reports personal fees for consultant/advisory role, research funding, and speaking engagements from MSD-Merck; consultant/advisory role, research funding, speaking engagements, and grant support from Roche Farma; consultant/advisory role, speaking engagements, and grant support from Bristol Myers Squibb; consultant/advisory role from Novartis and Pierre Fabre; consultant/advisory role and speaking engagements from Amgen; and research funding from Celgene, outside the submitted work. JTB reports grants for institutional funding for doing research from AbbVie, Alliance, Amgen, Ascentage Pharma Group, AstraZeneca, Bayer, Boston Biomedial, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech-Roche, Hutchison, Immunomedics, Janssen, MT Group, Nektar, Pfizer, Polynoma, Seattle Genetics, Serono-EMD, Tesaro, TG Therapeutics, Biodesix, Exact Sciences, Boehringer Ingleheim, Laekna, Novocure, Daiichi-Sankyo, Mirati Therapeutics, and Tarveda Therapeutics, during the conduct of the study. YJ, CW, UD, AC, JPZ, and TT report employment and stock ownership from Novartis. PAF reports personal fees for advisory board from Celgene, Merck Sharp & Dohme, Macrogenics, Eisai, Puma, Lilly, and AstraZeneca; lectures from Daiichi-Sankyo, Merck Sharp & Dohme, and Lilly; and research support from Cepheid and Novartis, outside the submitted work. PN has declared no conflicts of interest. Novartis made the study protocols available for MONALEESA-3 at the time of primary publications. Individual participant data will not be made available.DJS reports board of directors (stock) and travel expenses from BioMarin; stock ownership, research funding, and travel expenses from Pfizer; advisory board, consulting, research funding, and travel expenses from Novartis; consulting from Eli Lilly; and stock ownership from Amgen and Seattle Genetics. SC reports that his institution received grants and personal fees for advisory boards from Novartis, Pfizer, Hoffmann-La Roche, and Eli Lilly, outside the submitted work. GJ reports personal fees from Novartis, during the conduct of the study; grants, personal fees, and non-financial support from Novartis, Roche, and Pfizer; personal fees and non-financial support from Lilly, Amgen, BMS, and AstraZeneca; personal fees from AbbVie and Daiichi-Sankyo; and non-financial support from Med-immune and Merck KGaA, outside the submitted work. MDL reports personal fees for speaker honoraria and advisory board honoraria from Novartis, AstraZeneca, Eli Lilly, and Pierre Fabre, outside the submitted work. SI reports grants from AstraZeneca, Pfizer, Eisai, and Daewoong; advisory and personal fees from AstraZeneca, Novartis, Hanmi, Pfizer, Eisai, Amgen, MediPacto, Roche, Eli Lilly, MSD, and GlaxoSmithKline; and non-financial support from Novartis. KP reports personal fees for advisory board from Novartis, AstraZeneca, Roche, Pfizer, and BMS, outside the submitted work. GVB reports personal fees for advisory board from Novartis and Eli Lilly, outside the submitted work. MM reports personal fees for speaker honoraria and honoraria for participation in advisory boards from Lilly and Pfizer; honoraria for participation in advisory boards from AstraZeneca, GlaxoSmithKline, Pharmamar, and Taiho Oncology; and research grants and honoraria for participation in advisory boards from Novartis and Roche-Genentech, outside the submitted work. AN reports consulting/advisory role, travel/accommodation/expenses, and research funding from Novartis and consulting/advisory role from Amgen during the conduct of the study. GSS reports institutional reimbursement for patient accrual and education and steering committee activities from Novartis and institutional research support from Merck, AstraZeneca, and Roche, outside the submitted work. LDLC-M reports personal fees for consultant/advisory role, research funding, and speaking engagements from MSD-Merck; consultant/advisory role, research funding, speaking engagements, and grant support from Roche Farma; consultant/advisory role, speaking engagements, and grant support from Bristol Myers Squibb; consultant/advisory role from Novartis and Pierre Fabre; consultant/advisory role and speaking engagements from Amgen; and research funding from Celgene, outside the submitted work. JTB reports grants for institutional funding for doing research from AbbVie, Alliance, Amgen, Ascentage Pharma Group, AstraZeneca, Bayer, Boston Biomedial, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech-Roche, Hutchison, Immunomedics, Janssen, MT Group, Nektar, Pfizer, Polynoma, Seattle Genetics, Serono-EMD, Tesaro, TG Therapeutics, Biodesix, Exact Sciences, Boehringer Ingleheim, Laekna, Novocure, Daiichi-Sankyo, Mirati Therapeutics, and Tarveda Therapeutics, during the conduct of the study. YJ , CW, UD, AC, JPZ , and TT report employment and stock ownership from Novartis. PAF reports personal fees for advisory board from Celgene, Merck Sharp & Dohme, Macrogenics, Eisai, Puma, Lilly, and AstraZeneca; lectures from Daiichi-Sankyo, Merck Sharp & Dohme, and Lilly; and research support from Cepheid and Novartis, outside the submitted work. PN has declared no conflicts of interest.The study was funded by Novartis Pharmaceuticals Corporation.
Hamilton, E., Infante, J.R., Targeting CDK4/6 in patients with cancer. Cancer Treat Rev 45 (2016), 129–138.
Fry, D.W., Harvey, P.J., Keller, P.R., et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:11 (2004), 1427–1438.
Finn, R.S., Dering, J., Conklin, D., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res, 11(5), 2009, R77.
Slamon, D.J., Neven, P., Chia, S., et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:24 (2018), 2465–2472.
Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:18 (2016), 1738–1748.
Slamon, D.J., Neven, P., Chia, S., et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382:6 (2020), 514–524.
Im, S.A., Lu, Y.S., Bardia, A., et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381:4 (2019), 307–316.
Sledge, G.W. Jr., Toi, M., Neven, P., et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6:1 (2019), 116–124.
Goetz, M.P., Toi, M., Campone, M., et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:32 (2017), 3638–3646.
Turner, N.C., Slamon, D.J., Ro, J., et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379:20 (2018), 1926–1936.
Tripathy, D., Im, S.-A., Colleoni, M., et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre-or perimenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. SABCS, 2020 Poster PD2-04.
National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available at http://Ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm Accessed June 1, 2021.
Robins, J.M., Tsiatis, A.A., Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods 20:8 (1991), 2609–2631.
Infante, J.R., Cassier, P.A., Gerecitano, J.F., et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res 22:23 (2016), 5696–5705.
AstraZeneca. Faslodex (fulvestrant) prescribing information. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021344s015lbl.pdf Accessed June 1, 2021.
James, A.D., Schiller, H., Marvalin, C., et al. An integrated assessment of the ADME properties of the CDK4/6 inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data. Pharmacol Res Perspect, 8(3), 2020, e00599.
Samant, T.S., Huth, F., Umehara, K., et al. Ribociclib drug-drug interactions: clinical evaluations and physiologically-based pharmacokinetic modeling to guide drug labeling. Clin Pharmacol Ther 108:3 (2020), 575–585.
